We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Genetic Risk Factor Identified for Anxiety Disorders

By LabMedica International staff writers
Posted on 11 Apr 2017
Several newly discovered variants of the GLRB gene were associated with increased risk of developing anxiety disorders, including agoraphobic cognitions, increased startle response, and fear network activation, pointing to a potential neurogenetic pathway.

Mental, social, environmental, and inherited factors play roles in development of anxiety disorders. More...
The study, conducted by a research team from Julius-Maximilians-Universität Würzburg (JMU; Würzburg, Bavaria, Germany), involved over 5000 voluntary participants and 500 patients afflicted by panic disorder. The researchers pinpointed at least 4 variants of the GLRB (glycine receptor B) gene as risk factors for anxiety and panic disorders. High-resolution images of the brain activities of study participants provided additional clues.

Among people who suffer from anxiety and panic disorders, some may have an extreme fear of spiders or other objects, while others have breathing difficulties and accelerated heart beat in small rooms or large gatherings of people. With some afflicted persons, the anxiety attacks occur for no apparent cause. Many patients suffer from detrimental impacts on their everyday lives, often having problems at work and withdrawing from social contacts.

How are fear and anxiety triggered? How do anxiety disorders arise and evolve? Scientists from Münster, Hamburg, and Würzburg have been looking into these questions within the scope of the Deutsche Forschungsgemeinschaft (DFG)-funded Collaborative Research Center (CRC) TR 58. CRC members obtained the new results in cooperation with researchers from the "PanikNetz" panic network (Germany).

GLRB had been known for some time in connection with a different disease: "Some mutations of the gene cause a rare neurological disorder called hyperekplexia," said Prof Jürgen Deckert, of the CRC and JMU University Hospital. Hyperekplexia patients are permanently hypertonic and show pronounced startle responses, which may even cause sufferers to fall involuntarily. Similar to persons suffering from anxiety disorders, these patients develop behavior to avoid potentially frightening situations.

The GLRB mutations that have now for the first time been associated with anxiety and panic disorders are different from those of hyperekplexia. They occur more frequently and presumably entail less severe consequences. But they, too, trigger overshooting startle responses, and as a result may excessively activate the brain's "fear network".

"The results point to a hitherto unknown pathway of developing an anxiety disorder," said Prof Deckert. Further investigations are necessary to determine whether these findings can be harnessed to develop new therapies. For example, it is conceivable to bring the "fear network" that is misregulated by the GLRB variants back on track by administering drugs, possibly in addition to psychology-based behavior therapy.

The study, by Deckert J et al, was published online February 7, 2017, in the journal Molecular Psychiatry.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.